TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of subjects with treatment-emergent safety issues
Endpoint domain: Adverse events/effects
Primary endpoint: Expired air CO Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Sunitinib Malate
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Surgery After 90 Days of Treatment With SM
Endpoint domain: Adverse events/effects
Primary endpoint: Disease control at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal rating scale (VRS) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of solicited local and general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Urinary Glycosaminoglycan (GAG) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patient reported postoperative UUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of Isoflurane in coronary sinus blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altomare ODS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summary of Geometric Mean Titers of Japanese Encephalitis Virus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 12 Week Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Height Standard Deviation Score (SDS) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Standard Deviation Score (SDS) at Last Measurement After Final Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospitalizations and emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of positivity for Acute Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: General nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in patient's comprehensive quality of life composite
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Movement behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Communication behaviour
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of Aurixim
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nerve conductivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropathy related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of CIPN by CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Modified Clinical Test of Sensory Integration of Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Related Serious Adverse Events (SAEs) in Pregnant and Postpartum Women Taking Once-weekly RPT + INH
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Grade 2 Adverse Events (AEs) Judged to be Related to Study Drug Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With All Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of split-virion influenza A (H1N1) vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety information on ADACEL® vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in bone density and geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall confirmed objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of Child Maltreatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin Collagen/Elastin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opioid consumption in the intraoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in the postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worst pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rehospitalisation due to exacerbation of heart failure
Endpoint domain: Mortality/survival
Primary endpoint: SKV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in levels of PAR or PARP-1 before and after study treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute lymphocyte count (ALC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: success of inferior alveolar nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in protein carbonyls in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in C-reactive protein in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arm length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid Arm circumference (MAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days until complete resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of adipocyte markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Operation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of subjects with undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Efficacy in Preventing Virologically-Confirmed Dengue Fever
Endpoint domain: Mortality/survival
Primary endpoint: Proportion with morphological and/or perfusion changes due to CF lung disease after chest MRI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with impairments in pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cessation of per rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of urinary tract infections (UTI) complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Experiencing a Maximum Grade ≥ 2 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Best Overall Response (BOR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 18F-FLT-PET imaging for neuroblastoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of ischemia shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of complications after pancreatic surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in total FLS manual skills scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of a pulmonary complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: occurrence of a kidney complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose of fostamatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Momentary Drug Liking VAS maximum effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients using a CVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical changes in COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants developing delirium post-operatively
Endpoint domain: Adverse events/effects
Primary endpoint: Soft tissue thickness gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sensitivity and specificity of epigenetic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive and prognostic accuracy of a panel of SNPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief from clinical depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of the maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Laparotomy Conversion During OS Technique
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of TRE on glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Cytogenetic Response (MCyR) at 6 Months Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Beck Depression Inventory II score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor functional age determined by HD-sEMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor functional age determined by accelerometer signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's ability to answer inference questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: GMCs of HPV-specific antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants' assessment of Propel Sinus Stent vs Bioabsorbable Nasal Dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle Sympathetic Nerve Activity Burst Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception during dressing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the number of Accident and Emergency (A&E) visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency and time of occurrence of blood leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intubation parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: R5-R20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IL-2
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in NT-proBNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change of blood pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of TLL018
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence / absence of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: World Health Organization Quality of Life-BREF (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Morningness-eveningness questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in quality of life from baseline - ASK Nasal-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life from baseline - SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MP-424 area under the plasma concentration-time curve (AUC) from 0 to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POST scores > 3
Endpoint domain: Adverse events/effects
Primary endpoint: Darunavir clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Darunavir volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Darunavir absorption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Darunavir area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Darunavir maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor-cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: International Prostate Symptom Score (I-PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of regorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of diagnostic tests required for resolution
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time required to achieve diagnostic resolution
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Medical Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Wean Off CPAP at the First Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in tonic EAdi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bone voids repairing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With B-lines ≤ 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ObsQoR-11 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of post dural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Cosmetic result of surgical incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Short Physical Performance Battery Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communicative Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient's Activation Measure (PAM-13)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utilization of rehabilitative treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of terminal hairs in the target area of the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of vellus hairs in the target area of the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse event frequency and intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dorsal Caudate (DCA) GABA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Dorsal Caudate (DCA) Glx Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Medial Prefrontal Cortex (MPFC) GABA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Medial Prefrontal Cortex (MPFC) Glx Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Yale-Brown obsessive-compulsive scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treadmill exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: markers of apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Severity of Adverse Events After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Local or Systemic Reactogenicity After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Successful donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vibratory Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Minimum Detectable Angle of Dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence density of multidrug-resistant organisms (MDRO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: QT and corrected QT (QTc) intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients included and validated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: culture-confirmed influenza-illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Adverse Events of Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Dypnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in intra-ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Shoulder Instability (WOSI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of Sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of GDC-0853
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of GDC-0853
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Measurable Concentration [AUC (0-t)] of GDC-0853
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient scores on Oxford, Womac, and Knee Society scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MelaFind scores for pigmented skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnostic accuracy of PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ACh induced Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-Stent Late Lumen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of Participants in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Final Extent Inhibition of Platelet Aggregation (IPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Slope of Extent IPA Offset Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: arterial pO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of subclinical enthesitis and synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of VO2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes